Ovarian cancer: what nurses should know and how to communicate with patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Background. Ovarian cancer is a leading cause of female cancer mortality; late diagnosis and complex care pathways necessitate strong nursing involvement. Objective. To systematize practical, nurse-led algorithms for prevention and early detection, genetic testing (BRCA/HRD), treatment preparation, and longitudinal support of patients with ovarian cancer.

Methods. Narrative synthesis of current clinical guidelines and practice protocols, complemented by authors’ perspectives on multidisciplinary coordination and communication.

Results. 1. Population screening is not recommended; CA-125/HE4 and transvaginal ultrasound are used only when clinically indicated. 2. Red flags: persistent bloating/early satiety, pelvic pain, urinary symptoms, unexplained fatigue or weight loss lasting >2–3 weeks. 3. BRCA/HRD testing is mandatory in high-grade serous OC and guides maintenance therapy (PARP inhibitors ± bevacizumab). 4. Nursing priorities: fast navigation, perioperative and chemotherapy preparation, toxicity/adherence monitoring, integration with palliative and psycho-oncology services, and ethical communication.

Conclusions. Nursing professionals serve as pivotal care coordinators, improving timeliness, continuity, and quality of life for women with ovarian cancer.

About the authors

Svetlana V. Khokhlova

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Author for correspondence.
Email: info@rusvrach.ru
SPIN-code: 6009-4616

Doctor of Medical Sciences, Professor at the Department of Oncology and Palliative Medicine, Russian Medical Academy of Continuous Professional Education; Head of the Oncology Department of Antitumor Drug Therapy, Gynecology and Perinatology

Russian Federation, Moscow

Valentina M. Nechushkina

Privolzhsky Research Medical University

Email: info@rusvrach.ru
ORCID iD: 0000-0002-1232-6572
SPIN-code: 8523-6798

Doctor of Medical Sciences, Professor at the Department of Oncology, Radiation Therapy and Radiation Diagnostics, Deputy Director of the Scientific and Educational Center “Eurasian Oncology Program ‘EAFO’”

Russian Federation, Nizhny Novgorod

References

  1. Волчегорский И.А., Важенин А.В., Алексеева А.П. Сравнительный анализ стоимости «единицы эффекта» препаратов поддерживающей терапии для женщин, получающих лучевую терапию после хирургического лечения рака тела матки. Врач. 2023 (2): 34–37. [Volchegorskiy I.A., Vazhenin A.V., Alekseeva A.P. Comparative analysis of the cost of «unit of effect» of maintenance therapy drugs for women receiving radiation therapy after surgical treatment of endometrial cancer. Vrach. 2023 (2): 34–37]. https: //doi.org/10.29296/25877305-2023-02-07.
  2. Клинические рекомендации Минздрава России. Рак яичников/рак маточной трубы/первичный рак брюшины. Ассоциация онкологов России; 2024. Одобрено Научно-практическим советом Минздрава России. [Clinical Guidelines of the Ministry of Health of the Russian Federation. Ovarian cancer/fallopian tube cancer/primary peritoneal cancer. Russian Association of Oncologists; 2024. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation].
  3. Практические рекомендации по лечению злокачественных опухолей RUSSCO. Рак яичников, первичный рак брюшины и рак маточных труб. 13-е изд. М.: Российское общество клинической онкологии; 2024. [RUSSCO Practical Guidelines for the Treatment of Malignant Tumors. Ovarian cancer, primary peritoneal cancer and fallopian tube cancer. 13th ed. Moscow: Russian Society of Clinical Oncology; 2024].
  4. Солопова А.Г., Блинов Д.В., Ачкасов Е.Е. и др. Методы оценки качества жизни у женщин со злокачественными новообразованиями репродуктивной системы. Врач. 2023; 34 (1): 10–19. [Solopova A.G., Blinov D.V., Achkasov E.E. et al. Methods for assessing quality of life in women with malignant neoplasms of the reproductive system. Rach. 2023; 34 (1): 10–19]. doi: 10.29296/25877305-2023-01-02.
  5. Grossman D.C., Curry S.J., Owens D.K. et al. US Preventive Services Task Force. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018; 319 (6): 588–594. doi: 10.1001/jama.2017.21926.
  6. IARC. Global Cancer Observatory: Cancer today. Lyon, France: International Agency for Research on Cancer; 2022. [Электронный ресурс]. URL: https: //gco.iarc.who.int/today (дата обращения: 20.09.2025).
  7. Ledermann J.A., Matias-Guiu X., Amant F. et al. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024; 35 (3): 248–266. doi: 10.1016/j.annonc.2023.11.015.
  8. Liu J., Fleming G.F., Westin S.N. et al. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024; 22 (8): 512–519. doi: 10.6004/jnccn.2024.0052.
  9. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2024. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2024.
  10. Pellegrino B., Capoluongo E.D., Bagnoli M. et al. Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial. ESMO Open. 2025 Jan; 10 (1): 104091. doi: 10.1016/j.esmoop.2024.104091.
  11. Sideris M., Menon U., Manchanda R. Screening and prevention of ovarian cancer. Med J Aust. 2024; 220 (5): 264–274. doi: 10.5694/mja2.52227.
  12. World Ovarian Cancer Coalition. Ovarian Cancer Key Stats [Internet]. 2024 [cited 2024 Sep 20]. Available from: https: //worldovariancancercoalition.org/about-ovarian-cancer/key-stats/

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).